Psychedelics Market Trends: H1 2026 Review and Forecast
The psychedelic medicine market is moving swiftly from speculative research mode toward an institutional, prescription-oriented framework as federal policy in the US becomes more supportive.
President Donald Trump’s April 18 executive order on ibogaine and other psychedelic therapies helped trigger a sharp rally in psychedelic biotech names as investors priced in faster regulatory timelines and broader clinical acceptance.
The executive order directs the Food and Drug Administration (FDA) to speed up the review of eligible drugs, expands access through Right to Try and allocates US$50 million in federal research funding to match state investments.
Since then, the FDA has published a finalized version of guidance aimed at helping researchers studying the therapeutic benefits of psychedelics navigate the unique challenges of such investigations.
A public hearing on the issue is set for September 14.
The Massachusetts House of Representatives also attached a bill to a major economic development omnibus spending bill allowing the use of psychedelics to treat mental health conditions. And earlier this year, former FDA Commissioner Marty Makary suggested the first approval for a psychedelic drug could occur as early as the summer of 2026.
These tailwinds are setting the stage for a pivotal year, reshaping the investment thesis for psychedelic biotech.
Psychedelics market performance and investor sentiment
The psychedelic medicine sector has been on a rally after a sharp uptick following Trump’s executive order, posting compelling year-to-date gains that signal a broader resurgence in investor confidence.
Leading the charge, the Psychedelic Invest Index, a proprietary, market-cap-weighted index designed to track the total market performance of publicly traded companies in the psychedelics sector, is up by over 35 percent.
Clinical-stage heavyweights have also seen massive gains, particularly Definium Therapeutics (NASDAQ:DFTX), a company with positive Phase 3 trial results for its LSD-based candidate (DT120) in major depressive disorder. Its share price is up a significant 236.67 percent year-to-date.
Compass Pathways (NASDAQ:CMPS) and AtaiBeckley (NASDAQ:ATAI), up 76.52 and 74.45 percent this year, respectively, are also advancing trials for treatment-resistant depression.
For retail and institutional investors using broader basket exposure, the AdvisorShares Psychedelics ETF (ARCA:PSIL) has delivered a return of nearly 40 percent so far in 2026.
“Psychedelics … are up very nicely year-to-date and over the past year,” said Dan Ahrens, managing director, COO and CIO at AdvisorShares, and also the primary portfolio manager for PSIL.
“There’s a lot more societal acceptance … and rulings from the FDA in acceptance of alternative treatments that are needed for PTSD, traumatic brain injury, untreatable depression and all sorts of uses.”
Compared to the cannabis sector, which has…
Read More: Psychedelics Market Trends: H1 2026 Review and Forecast